AMICUS THERAPEUTICS, INC.
AMICUS THERAPEUTICS, INC. (FOLD): 22 pipeline candidates · 14 upcoming catalysts · ~9 mo cash runway · 20 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
8.5 months
D/E 2.46 · 0% dilution
Lead: Approved
22 candidates
14 upcoming, next in ~196d
0 buys · 2 sells (180d)
A transparent, data-derived signal for AMICUS THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.5B
Cash
$217.3M
Quarterly Burn
$142.7M
Runway
8.5 mo
Revenue
$185.2M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (22 candidates)
| Drug | Phase |
|---|---|
| Alglucosidase Alfa | Phase 3 |
| Alglucosidase alfa or Avalglucosidase alfa | Phase 3 |
| AT2221 | Phase 3 |
| ATB200 | Phase 3 |
| Cipaglucosidase Alfa | Phase 3 |
| DMX-200 | Phase 3 |
| Duvoglustat | Phase 3 |
| ERT | Phase 3 |
| Galafold | Approved |
| Galafold® | Approved |
Showing 10 of 22 candidates. Sign up for full pipeline.
Upcoming Catalysts (14)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
297
Total value held
$4.81B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 33,879,048 | $489.9M |
| vanguard capital management llc | 28,047,114 | $405.6M |
| ubs group ag | 15,957,913 | $230.8M |
| pentwater capital management lp | 14,000,000 | $202.4M |
| vanguard portfolio management llc | 13,974,932 | $202.1M |
| state street corp | 12,893,897 | $186.4M |
| fil ltd | 12,560,028 | $181.6M |
| goldman sachs group inc | 11,556,008 | $167.1M |
| qube research & technologies ltd | 8,809,340 | $127.4M |
| hbk investments l p | 8,783,448 | $127.0M |
Showing top 10 of 297 institutional holders of AMICUS THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in AMICUS THERAPEUTICS, INC.'s pipeline?
AMICUS THERAPEUTICS, INC. (FOLD) has 22 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AMICUS THERAPEUTICS, INC.'s lead drug candidate?
AMICUS THERAPEUTICS, INC.'s most advanced tracked candidate is Alglucosidase Alfa (Phase 3) for Pompe Disease (Late-onset).
What is AMICUS THERAPEUTICS, INC.'s next catalyst?
AMICUS THERAPEUTICS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects With F" — expected December 31, 2026.
What is AMICUS THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AMICUS THERAPEUTICS, INC. has approximately 8.5 months of cash runway.
What is AMICUS THERAPEUTICS, INC.'s market capitalization?
AMICUS THERAPEUTICS, INC.'s market capitalization is approximately $4.5B.
Get the full picture on AMICUS THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.